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Purpose: Diabetic retinopathy and nephropathy are microvascular complications in patients with diabetes that are
considered to be related. Pigment epithelium-derived factor (PEDF), a strong inhibitor of angiogenesis, is significantly
elevated in the blood of diabetic patients, especially those with proliferative diabetic retinopathy (PDR). The level of
PEDF in the blood, on the other hand, is reported to be low in a diabetic nephropathy. The aim of this study was to
determine the relationship between PEDF and renal function in patients with diabetic retinopathy.
Methods: A total of 243 type 2 diabetic patients were studied. The relationship between the diabetic retinopathy and levels
of PEDF, HbA1c, blood urea nitrogen (BUN), and creatinine were evaluated.
Results: The mean plasma PEDF level in patients with PDR (7.69±6.14 µg/ml; mean±standard error) was significantly
higher than that of mild-to-moderate nonproliferative diabetic retinopathy (5.07±4.37 µg/ml, p=0.02). The level of BUN
and creatinine increased significantly as the stage of diabetic retinopathy advanced. The plasma PEDF levels were
significantly correlated with the levels of BUN and creatinine (r=0.54, p<0.0001; r=0.57, p<0.0001, respectively).
Conclusions: The levels of plasma PEDF increases with advances in both diabetic retinopathy and nephropathy. Thus,
increased levels of PEDF in the blood may indicate microvascular damages in diabetic patients and may be predictor of
the progression of retinopathy and nephropathy.
Pigment epithelium-derived factor (PEDF) is a potent
inhibitor  of  angiogenesis  originally  isolated  from
conditioned-medium  of  cultured  human  retinal  pigment
epithelial  cells  [1].  PEDF  inhibits  retinal  endothelial  cell
growth,  migration,  and  suppresses  ischemia-induced
neovascularization [1,2].
Diabetic retinopathy is a microvascular complication of
diabetic mellitus, and is a major cause of adult blindness [3].
The  level  of  intraocular  PEDF  decreases  with  advancing
stages of diabetic retinopathy [4-6]. On the other hand, we
recently found that plasma levels of PEDF are significantly
higher in patients with type 2 diabetes and especially high in
patients with proliferative diabetic retinopathy [7].
Diabetic nephropathy, which causes renal failure, is also
a serious complication of diabetic mellitus [8]. In contrast to
the report of PEDF levels in the blood of patients with diabetic
retinopathy [7], Wang et al. [9] reported that the PEDF level
in the kidney is down-regulated and the serum PEDF level are
lower in a rat model of diabetic nephropathy.
Both  retinopathy  and  nephropathy  are  common
microvascular  complications  associated  with  diabetes.
Previous studies have shown these conditions are strongly
associated, and there have been reports that renal dysfunction
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is a risk factor for the development and worsening of diabetic
retinopathy [10,11].
The  findings  in  the  two  previous  reports  [7,8]  are
contradictory; one showed that plasma PEDF level is high in
patients with diabetic retinopathy [7], while the other showed
that the plasma PEDF level is low in a rat model of diabetic
nephropathy  [8].  The  aim  of  this  study  was  to  determine
whether the plasma level of PEDF is correlated with the renal
function in patients with diabetic retinopathy.
METHODS
Subjects: This study was conducted according to the tenets of
the Declaration of Helsinki and was performed after receiving
approval from the Institutional Review Committee of Kansai
Medical University. An informed consent was obtained from
all patients.
Blood samples were collected from 243 type 2 diabetic
patients  (125  men  and  118  women,  ages  18  to  87  years,
61.7±9.3  years;  mean±standard  deviation)  at  the  Kansai
Medical University Hospital.
Examination  of  diabetic  retinopathy:  All  patients  with
diabetic  mellitus  underwent  a  standard  ophthalmic
examination at the time of blood sample collection. The stage
of diabetic retinopathy was determined by ophthalmoscopy
and fluorescein angiography, and the patients were classified
according to the severity scale of diabetic retinopathy [12].
The scale was: no apparent diabetic retinopathy (NDR), mild
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992to moderate nonproliferative diabetic retinopathy (M-NPDR),
severe nonproliferative diabetic retinopathy (S-NPDR), and
proliferative diabetic retinopathy (PDR). Patients with other
ocular diseases such as uveitis, glaucoma, age-related macular
degeneration,  retinal  degeneration,  and  retinal  vascular
thrombosis were excluded. However, diabetic patients with
simple cataracts were included.
Pigment epithelium-derived factor levels in plasma: PEDF
levels in plasma were measured with an ELISA Kit as per the
manufacture's  instructions  (PEDF  Sandwich  ELISA  Kit;
Chemicon®  International,  Temecula,  CA).  Briefly,  blood
samples  were  collected  in  tubes  containing  EDTA,  and
platelet-poor plasma was prepared by centrifugation (3000
rpm, 20 min) and stored at -80 °C before use. Before the assay,
samples were thawed on ice and urea was added to a final
concentration of 8 M. After incubation on ice for 1 h, samples
were diluted in assay diluent, then immediately applied to the
assay plates and measured according to the manufacturer’s
protocol.
Laboratory examination: The level of HbA1c was determined
by  automated  glycohemoglobin  analyzer  (HLC-723G8;
TOSHO Co., Tokyo, Japan), and blood urea nitrogen (BUN)
and  creatinine  were  determined  by  blood  autoanalyzer
(AU540;  Olympus,  Tokyo,  Japan)  according  to  the
manufacturer’s protocols.
Statistical analysis: The results are expressed as the mean
±standard  error  of  the  mean  (SEM),  and  the  data  were
analyzed  statistically  by  one  way  analysis  of  variance
(ANOVA) with Fisher protected least-significant difference
(PSLD)  test  when  comparing  groups.  The  correlations
between PEDF and BUN or creatinine were determined by the
Pearson's  product  moment  correlation  coefficient  (r).  A  p
value <0.05 was accepted as significant.
RESULTS
Plasma pigment epithelium-derived factor levels and stage of
diabetic retinopathy: The level of plasma PEDF increased as
the stage of diabetic retinopathy advanced: 5.29±5.10 µg/ml
in patients with NDR (n=20, 63.9±10.3 years); 5.07±4.37 µg/
ml  in  patients  with  M-NPDR  (n=37,  66.6±9.1  years);
6.61±6.20 µg/ml in patients with S-NPDR (n=98, 62.9±8.1
years); and 7.69±6.14 µg/ml in patients with PDR (n=88,
57.9±9.7 years) (Figure 1A). The level of PEDF in the PDR
group was significantly higher than that of M-NPDR group
(p=0.02).
HbA1c and stage of diabetic retinopathy: The level of HbA1C
was 7.2±0.3% in the NDR group, 7.4±0.2% in the M-NPDR
group, 7.3±0.2% in the S-NPDR group, and 7.4±0.2% in the
PDR group. The differences between the groups were not
significant.
Blood  urea  nitrogen,  creatinine,  and  stage  of  diabetic
retinopathy:  The  level  of  BUN  increased  as  the  stage  of
diabetic retinopathy advanced: 15.6±1.0 mg/dl in the NDR
group (n=17), 18.5±1.1 mg/dl in the M-NPDR group (n=24),
19.9±0.9  mg/dl  in  the  S-NPDR  group  (n=59),  and
27.1±2.5 mg/dl in the PDR group (n=65) (Figure 1B). The
level of BUN in the PDR group was significantly higher than
Figure 1. Pigment epithelium-derived factor (PEDF), blood urea
nitrogen (BUN), and creatinine levels in 243 type 2 diabetic patients.
A: PEDF levels and the stage of diabetic retinopathy. B: BUN levels
and the stage of diabetic retinopathy. C: Creatinine levels and the
stage of diabetic retinopathy. Abbreviations: NDR represents no
apparent diabetic retinopathy, M-NPDR represents mild to moderate
nonproliferative  diabetic  retinopathy,  S-NPDR  represents  severe
nonproliferative diabetic retinopathy, PDR represents proliferative
diabetic retinopathy, and the asterisk represents a p<0.05.
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p=0.01, p=0.003, respectively).
The level of creatinine also increased as the stage of
diabetic retinopathy advanced: 0.69±0.06 mg/dl in the NDR
group, 0.71±0.06 mg/dl in the M-NPDR group, 1.01±0.19 mg/
dl in the S-NPDR group, and 1.94±0.30 mg/dl in the PDR
group (Figure 1C). The level of creatine in the PDR group was
significantly higher than that in the NDR, M-NPDR, and S-
NPDR  groups  (p=0.01,  p=0.005,  p=0.008,  respectively).
These  analyses  were  performed  on  165  of  non-selected
diabetic  patients  who  had  complete  sets  of  PEDF,  BUN,
creatinine, and HbA1c data.
Correlation between pigment epithelium-derived factor level
and blood urea nitrogen and creatinine levels: The plasma
PEDF levels increased with increasing BUN and creatinine
levels (Figure 2, n=165). The correlation between PEDF and
BUN was significant (r=0.54, p<0.0001), and the correlation
between PEDF and creatinine was also significant (r=0.57,
p<0.0001).
Figure 2. Relationship between pigment epithelium-derived factor
and renal function. A: Correlation between pigment epithelium-
derived  factor  (PEDF)  levels  and  blood  urea  nitrogen  shows  a
correlation coefficient of r=0.54 at a significance level of p<0.0001.
B:  Correlation  between  PEDF  levels  and  creatinine  shows  a
correlation coefficient of r=0.57 at a significance level of p<0.0001.
DISCUSSION
PEDF  is  synthesized  in  a  wide  range  of  human  tissues
including  the  lung,  brain,  kidney,  adipose  tissues,  and
especially in the liver [1,13]. The multiple sites may be the
cause of the high levels of PEDF in the blood [13].
We recently reported that plasma PEDF level in diabetic
patients was significantly higher than that in controls, and the
level was especially high in patients with proliferative diabetic
retinopathy [7]. The results of this study confirmed those
findings.
Diabetic  retinopathy  and  nephropathy  are  both
microvascular complications associated with diabetes. The
results of several studies that have examined the relationship
between  diabetic  retinopathy  and  nephropathy  are  not
consistent [14]. We clearly demonstrated that levels of BUN
and creatinine increased significantly as the stage of diabetic
retinopathy advanced. These results support previous studies
that  showed  that  these  conditions  are  strongly  associated
[10,11]. In addition, plasma PEDF levels were significantly
correlated with the levels of both BUN and creatinine.
Several growth factors, most importantly, transforming
growth factor-β (TGF-β), vascular endothelial growth factor
(VEGF),  and  fibroblast  growth  factor  (FGF),  have  been
suggested  to  be  involved  in  the  pathogenesis  of  diabetic
nephropathy and retinopathy [15-19].
PEDF inhibits the migration of endothelial cells induced
by  VEGF  and  FGF  [1,2].  In  addition,  PEDF  has  been
suggested to be an anti-inflammatory cytokine [20]. PEDF
inhibits the expression of tumor necrosis factor-α (TNF-α),
VEGF,  monocyte  chemoattractant  factor-1  (MCP-1),  and
intercellular adhesion molecule-1 (ICAM-1) [20]. PEDF also
significantly inhibits the activity of advanced glycation end
products  (AGEs)  in  microvascular  endothelial  cells  [21].
From these observations, PEDF has been suggested to play a
protective  role  against  vascular  damages  by  suppressing
proliferative inflammatory responses to injuries in endothelial
cells.
Chronic,  low-grade  inflammation  is  responsible  for
diabetic  microangiopathy,  such  as  retinopathy  [22]  and
nephropathy [23]. Thus, the increase in the levels of PEDF in
the plasma of diabetic patients with diabetic retinopathy and
nephropathy may be a counteractive system that inhibits the
vascular damages in diabetic mellitus. Yamagishi et al. [13]
also  reported  that  serum  PEDF  levels  may  increase  as  a
counteractive  system  against  coronary  risk  factors  in  the
metabolic  syndrome.  Together  with  the  previous  report,
PEDF is most likely associated with metabolism and may be
associated with angiopathy.
In contrast to our results, an earlier study demonstrated
that the expression of PEDF was decreased at both the mRNA
and protein states in the kidney of diabetic rats induced by
streptozotocin. The PEDF levels in the serum in these rats
were also significantly decreased at the late stage of diabetes
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animals [9]. We still do not know the exact reason for this
discrepancy; however one reason may be that they used an
animal model of type 1 diabetes induced by streptozotocin,
whereas we examined humans with type 2 diabetes.
Although  we  found  that  the  levels  of  plasma  PEDF
increased  with  advances  in  both  diabetic  retinopathy  and
nephropathy, the level of intraocular PEDF has been shown
to  decrease  with  advancing  stages  of  diabetic  retinopathy
[4-6]. Because, PEDF is a potent anti-angiogenic and anti-
inflammatory cytokine [1,2,20,21], PEDF may be consumed
in  the  eye  with  diabetic  retinopathy  to  counteract  the
angiogenic and inflammatory responses of the endothelial
cell,  which  would  then  lead  to  lower  levels.  A  similar
mechanism  may  apply  to  diabetic  nephropathy  and  may
account for the decreased expression of PEDF in the kidney
of diabetic rats [9].
A more recent study found high levels of PEDF in the
serum of patients with end-stage renal disease [24] which is
compatible with our results. Because of the close relationship
between diabetic nephropathy and diabetic retinopathy and
because  both  of  these  conditions  result  in  diabetic
microangiopathy, it is more likely that PEDF is associated
with  the  metabolism  of  diabetic  patients  and  may  be
associated with the angiopathy.
Estimates of the prevalence of retinopathy are usually
based on direct examination of the anatomic retinal changes,
whereas  those  of  nephropathy  are  defined  by  functional
abnormalities such as microalbuminuria or overt proteinuria.
Further longitudinal studies with repetitive samples from the
same donor should be performed to determine the changes
with  time.  These  findings  should  answer  the  question  on
whether the increased levels of PEDF in the blood of patients
with  diabetic  retinopathy  would  indicate  microvascular
damage  and  may  be  used  to  predict  the  progression  of
retinopathy and nephropathy.
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